MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Travere Therapeutics Inc

Fermé

17.95 2.87

Résumé

Variation du prix de l'action

24h

Actuel

Min

17.07

Max

18.05

Chiffres clés

By Trading Economics

Revenu

-5.5M

-60M

Ventes

12M

75M

BPA

-0.47

Marge bénéficiaire

-80.586

Employés

385

EBITDA

-4.6M

-45M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+95.93% upside

Dividendes

By Dow Jones

Prochains Résultats

5 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-138M

1.7B

Ouverture précédente

15.08

Clôture précédente

17.95

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Travere Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 févr. 2025, 13:58 UTC

Principaux Mouvements du Marché

Travere to Seek FDA OK of Filspari in Rare Kidney Disorder FSGS; Shares Rally

Comparaison

Variation de prix

Travere Therapeutics Inc prévision

Objectif de Prix

By TipRanks

95.93% hausse

Prévisions sur 12 Mois

Moyen 34.17 USD  95.93%

Haut 47 USD

Bas 22 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

13

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

17.455 / 20.98Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Travere Therapeutics Inc

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.